

Durham Research Online

Deposited in DRO:

10 June 2016

Version of attached file:

Accepted Version

Peer-review status of attached file:

Peer-reviewed

Citation for published item:

El-Hossary, Ebaa M. and Nissan, Yassin M. and Edkins, Katharina and Bruhn, Heike (2016) 'Synthesis and antibacterial activity of novel 2-(arylimino)thiazolidin-4-one and 2-(benzylidenehydrazono)-3-arylthiazolidin-4-one derivatives.', *Journal of applied pharmaceutical science.*, 6 (05). 007-017.

Further information on publisher's website:

<http://dx.doi.org/10.7324/JAPS.2016.60502>

Publisher's copyright statement:

© 2016 Ebaa M. El-Hossary et al. This is an open access article distributed under the terms of the Creative Commons Attribution License-NonCommercial-ShareAlikeUnported License (<http://creativecommons.org/licenses/by-nc-sa/3.0/>).

Additional information:

Use policy

The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for personal research or study, educational, or not-for-profit purposes provided that:

- a full bibliographic reference is made to the original source
- a [link](#) is made to the metadata record in DRO
- the full-text is not changed in any way

The full-text must not be sold in any format or medium without the formal permission of the copyright holders.

Please consult the [full DRO policy](#) for further details.

Synthesis and antibacterial activity of novel 2-(arylimino)thiazolidin-4-one and 2-(benzylidenehydrazono)-3-arylthiazolidin-4-one derivatives

Ebaa M. El-Hossary^{1,2,*}, Yassin M. Nissan³, Katharina Edkins⁴, Heike Bruhn⁵

¹ National Centre for Radiation Research & Technology, Egyptian Atomic Energy Authority, Ahmed El-Zomor St. 3, El-Zohoor Dist., Cairo, Egypt

² Institute of Pharmacy & Food Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany

³ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt

⁴ School of Medicine, Pharmacy and Health, Durham University, Stockton-on-Tees, United Kingdom

⁵ Institute for Molecular Infection Biology, SFB 630, University of Würzburg, Josef Schneider Str. 2, Bau 15, 97080 Würzburg, Germany

*Corresponding author:

National Centre for Radiation Research & Technology, Egyptian Atomic Energy Authority, Ahmed El-Zomor St. 3, El-Zohoor Dist., Cairo, Egypt.

P.O. Box: 29 Nasr City

Tel.: +2 0100 1072957

Fax: +2 02 22749298

E-mail: ebaa.elhossary@eaea.org.eg

1 **ABSTRACT**

2 The ongoing spread of multidrug-resistant bacteria demands an intensive search for new
3 antibacterial agents. In the present study, a series of new 1,3-thiazolidin-4-ones has been
4 synthesized and investigated for its *in vitro* antibacterial activity. The most potent antibacterial
5 compound **4c** was found to be active, at low micromolar range, against *Staphylococcus aureus*,
6 *Staphylococcus epidermidis*, *Enterococcus faecalis* and the pneumonic plague causative agent
7 *Yersinia pestis* with minimum inhibitory concentrations of 5 μ M, 2.5 μ M, 2.5 μ M and 5 μ M,
8 respectively. Compound **4c** showed the ability to kill *E. faecalis* JH212 strain with a minimum
9 bactericidal concentration of 5 μ M. Furthermore, compounds **9b** and **10a** inhibited the biofilm
10 formation in *S. epidermidis*, where they showed 70% to 80% inhibition at a concentration of 40
11 μ M.

12

13

14 **Key words:**

15 1,3-Thiazolidin-4-one

16 Antibacterial activity

17 Minimum inhibitory concentration

18 Minimum bactericidal concentration

19 Biofilm formation

20

21

22

23

24

1

2 INTRODUCTION

3 Currently, infectious diseases are the second leading cause of death worldwide. Bacterial resistance
4 against antibiotics is an increasing health problem in both community and hospital setting. It has a
5 noteworthy impact on the mortality rates, morbidity rates and the financial burden associated.
6 Although various novel antibacterial drugs had been introduced into the market in the past decades,
7 the prevalence of multidrug-resistant pathogens remains among the major health problems which
8 raises severe concern around the globe (Bassetti et al., 2013; Butler et al., 2013; Kumarasamy et al.,
9 2010; Lewis, 2013; Pendleton et al., 2013).

10 Staphylococci and Enterococci are Gram-positive bacteria that are responsible for several
11 community and hospital acquired infections. *Staphylococcus aureus* causes a wide range of
12 infections from simple skin and soft tissue infections to serious illnesses like pneumonia, infective
13 endocarditis and sepsis (Tong et al., 2015; Valour et al., 2013). *Staphylococcus epidermidis* is
14 regarded as the most frequent cause of nosocomial and indwelling medical device-associated
15 infections. It causes more persistent infections due to its high ability to resist antibiotic treatments
16 through biofilm formation (Gomes et al., 2014; Namvar et al., 2014; Otto, 2009).

17 Since the beginning of the antibiotic era, the isolation of multidrug resistant enterococci has
18 become increasingly common in hospital setting. *Enterococcus faecalis* and *Enterococcus faecium*
19 are the most predominant species, cultured from humans, representing more than 90% of clinical
20 isolates. *E. faecalis* infective endocarditis is still a very serious disease, associated with the
21 presence of highly gentamicin-resistant strains and in-hospital mortality rates around 20%
22 (Courvalin, 2006; Dahl and Bruun, 2013; de Perio et al. , 2006; Deshpande et al., 2007). On the
23 other hand, the gram-negative bacterium *Yersinia pestis* is the causative agent of pneumonic

plague; which is the most severe manifestation of plague. The mortality rates of pneumonic plague are approximately 100% in untreated cases (Pechous et al., 2015).

1,3-Thiazolidin-4-ones are a class of compounds that have shown potential as antibacterials (Aridoss et al., 2009; Gopalakrishnan et al., 2009; Jain et al., 2012; Poyraz et al., 2013; Sayyed et al., 2006; Verma and Saraf, 2008; Vicini et al., 2006; Vicini et al., 2008). Thiazolidin-4-ones have been found as inhibitors of the bacterial enzyme MurB; a key enzyme responsible for the synthesis of peptidoglycan (Andres et al., 2000). In this study, a series of 2-(arylimino)thiazolidin-4-ones and 2-(benzylidenehydrazono)-3-arylthiazolidin-4-ones was synthesized. The synthesized compounds were tested for their *in vitro* antibacterial activity against selected clinically important pathogenic microbes.

RESULTS AND DISCUSSION

Chemistry

The synthesis of the target 1,3-thiazolidin-4-one derivatives started with the conversion of the commercially available sulfanilamide **1** into the corresponding thioureido derivatives **2a-c** (Roth and Degering, 1945) when sulfanilamide **1** reacted with the appropriate isothiocyanate derivative (Scheme 1). The thioureido derivatives **2a-c** were then refluxed with an equimolar amount of chloroacetic acid in glacial acid to give the respective 4-(4-oxo-3-substitutedthiazolidin-2-ylideneamino)benzenesulfonamide derivatives **3a-c** (Scheme 1). IR spectra of compounds **3a-c** revealed strong characteristic intense bands at 1712-1724 cm⁻¹ which correspond to the carbonyl group of the 1,3-thiazolidin-4-one ring. ¹H-NMR spectra of compounds **3a-c** displayed singlets at 4.04-4.16 ppm for the two protons of the methylene (-CH₂-) of the 1,3-thiazolidin-4-one nucleus. ¹³C-NMR spectra of compounds **3a-c** exhibited new signals at 29.07-32.74 ppm, ascribed to the

1 methylene group, confirming the intramolecular cyclization and formation of the 1,3-thiazolidin-4-
2 one ring.

3 Similarly, compounds **4a-c** were synthesized by refluxing the thioureido derivatives **2a-c** with an
4 equimolar amount of diethyl bromomalonate in glacial acid (Scheme 1). IR spectra of the
5 compounds **4a-c** were characterized by the presence of two strong bands corresponding to the
6 carbonyl group of the ethylester moiety and the carbonyl group of the 1,3-thiazolidin-4-one ring at
7 1689-1751 cm^{-1} . ^1H -NMR spectra of compounds **4a-c** exhibited triplets and quartets corresponding
8 to the ethylester substituent at position 5. The synthesis of compounds **5a-c** was attained by
9 refluxing the corresponding thioureido derivatives **2a-c** with an equimolar amount of maleic
10 anhydride in glacial acid (Scheme 1). IR spectra of the 2-(4-oxothiazolidin-5-yl)acetic acid
11 derivatives **5a-c** showed two bands representing the carbonyl group of the 1,3-thiazolidin-4-one
12 nucleus and the carbonyl group of the acetic acid moiety at 1660-1708 cm^{-1} .

13 The 4-isothiocyanatobenzenesulfonamide **6** was obtained by stirring a solution of sulfanilamide **1** in
14 distilled water containing an equimolar amount of thiophosgen (El-Gaby et al., 2009). Compound **6**
15 was then stirred with an excess amount of hydrazine hydrate to give *N*-(4-sulfamoylphenyl)-
16 hydrazinecarbothioamide **7** (Sriram et al., 2009). The Schiff's bases **8a,b** were prepared by
17 refluxing compound **7** with an equimolar amount of the appropriate aldehyde in methanol (Scheme
18 2). ^1H -NMR spectrum of compound **8a** displayed signals at 10.32 and 12.05 ppm, which were
19 exchangeable in D_2O , confirming the presence of two NH groups of the hydrazinecarbothioamide.
20 The ^{13}C -NMR spectrum of compound **8b** was characterized by the appearance of a new signal at
21 39.66 ppm ascribed to the two carbon atoms of the $\text{N}(\text{CH}_3)_2$ group.

22 Additionally, ^1H -NMR spectra of compounds **8a,b** exhibited signals at 8.15 and 8.06 ppm,
23 respectively, for the imine proton of ($\text{N}=\text{CH}$). In a similar way to the synthetic pathway of the
24 target 1,3-thiazolidin-4-ones outlined in Scheme 1, the 2-(4-(substituted)benzylidene)-*N*-(4-

sulfamoylphenyl)-hydrazinecarbothioamides **8a,b** were cyclized into the corresponding 1,3-thiazolidin-4-one derivatives **9a,b** by reaction with an equimolar amount of monochloroacetic acid (Scheme 2). IR spectra of compounds **9a,b** revealed characteristic bands at 1732, 1697 cm^{-1} , respectively, which correspond to the carbonyl group of the 1,3-thiazolidin-4-one ring. ^1H -NMR spectra of compounds **9a,b** displayed signals at 4.13 and 4.09 ppm, respectively, for the two protons of the methylene group of the 1,3-thiazolidin-4-one ring.

In addition, ^1H -NMR spectrum of compound **9b** revealed a singlet at 2.97 ppm representing the 6 protons of the dimethylamino group. The Schiff's bases **8a,b** were also cyclized into the corresponding 1,3-thiazolidin-4-one derivatives **10a,b**, by refluxing with an equimolar amount of diethyl bromomalonate in glacial acetic acid (Scheme 2). IR spectra of compounds **10a,b** showed two bands for the two carbonyl groups; the ethyl ester moiety and the 1,3-thiazolidin-4-one ring at 1612-1739 cm^{-1} . ^1H -NMR spectra of compounds **10a,b** exhibited triplets and quartets representing the ethyl group of the ethyl ester substituent at position 5.

Finally, the synthesis of the 1,3-thiazolidin-4-one derivatives **11a,b** was attained by refluxing the corresponding Schiff's bases **8a,b**, with an equimolar amount of maleic anhydride in glacial acetic acid (Scheme 2). ^1H -NMR spectra of compounds **11a,b** revealed new signals at 10.86 and 10.75 ppm, respectively, corresponding to the one proton of the carboxylic OH group.

To confirm the cyclization pattern of the 1,3-thiazolidin-4-one ring, compound **3a** was subjected to x-ray crystallography measurement. Crystals suitable for X-ray diffraction were grown from dichloromethane solution by slow cooling. The structure could be determined in the triclinic space group P-1 with four symmetric independent molecules in the asymmetric unit ($Z' = 4$). This is due to a break in symmetry by the disorder of the central phenyl rings. The bond lengths and angles are all within normal ranges (Allen et al., 1987). The molecules of **3a** adopted two different conformations in this structure, with the angle between the thiazolidinone and the phenyl ring either

60° or -50° (**Figure 1a**). This has no influence on the overall packing and it is assumed that due to the comparable size of the phenyl ring and the sulfonamide terminal group, the phenyl ring can rotate rather freely. The crystal packing consists of pseudo-centrosymmetric dimers of **3a** stabilized through weak C-H...O hydrogen bonds (**Figure 1b**). These dimers are connected to the next dimer through N-H...O hydrogen bonds, between the terminal amide group and the C=O group of the thiazolidinone rings, linking the structure together along the crystallographic *b*-axis. An additional N-H...O hydrogen bond between the terminal amide group and the S=O group of the sulfonamide links the molecules along *b*. This packing results in the formation of stacks along the crystallographic *a*-axis which consist of alternate disordered and non-disordered molecules.

Antibacterial activity

All of the newly synthesized final compounds have been screened at a highest concentration of 40 μ M, for their *in vitro* antibacterial activity against selected clinically important pathogenic bacteria. These bacteria include the Gram-positive bacteria; *S. aureus* (Strains; 8325, HG001, MA12, RN1 and Xen29), *S. epidermidis* (Strains; RP62A, 195 and 047), *E. faecalis* JH212, *E. faecium* 6413 and the Gram-negative bacteria; *Escherichia coli* 536, *Pseudomonas aeruginosa*, *Y. pestis* KUMA and *Yersinia pseudotuberculosis* 252 01A. Staphylococci, Enterococci and *P. aeruginosa* belong to the so called “ESKAPE” pathogens; pathogenic bacteria that are responsible for the highest impact in bacterial resistance (Pendleton et al., 2013). Moreover, *S. aureus*, *S. epidermidis*, *P. aeruginosa*, and *E. coli* can cause persistent infections that are resistant to antibiotic treatments due to their ability to form biofilm (Romling and Balsalobre, 2012).

All the tested compounds have been evaluated for their *in vitro* antibacterial activity by measuring the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC). MIC is the lowest concentration of the tested compound that inhibits the visible growth of the tested

1 bacterial strain after overnight incubation while MBC is the lowest concentration of the tested
2 compound required to kill the tested bacterium. Antibacterial agents are usually considered
3 bactericidal if the MBC value doesn't exceed four folds the MIC value (French, 2006). All the
4 tested compounds showed MIC values higher than 40 μ M except compounds **4a** and **4c**.
5 Gentamicin and tetracycline were used in the test as reference drugs. The antibacterial activities of
6 compounds **4a** and **4c** are presented in Table 1.

7 Based on the results, mentioned in Table 1, it was found that the presence of ethylester at position 5
8 on the 1,3-thiazolidin-4-one ring is an essential feature for activity whereas the other congeners
9 with 5-unsubstituted (compounds **3a-c**) or 5-acetic acid side chain (compounds **5a-c**) are devoid of
10 activity. However, the nature of the substituent at position 3 was also critical for keeping compound
11 activity as only the methyl and the phenyl substituents (compounds **4a** and **4c**, respectively) were
12 able to maintain the antibacterial activity. This was evidenced by compound **4b** in which extending
13 the methyl into ethyl led to complete loss of activity (compound **4a** compared to compound **4b**).
14 Generally; compound **4c**, with a phenyl substitution at position 3 of the 1,3-thiazolidin-4-one
15 nucleus, showed lower MIC values when compared with the MIC values of compound **4a** with the
16 3-methyl substituent. In fact, in most cases, compound **4c** showed a double potency compared to
17 compound **4a**. The higher activity of the more lipophilic ethylester derivatives **4a** and **4c** compared
18 to the carboxylic acid derivatives **5a** and **5c** might be due to their higher ability to penetrate the
19 bacterial outer membrane. Additionally, these ethylester derivatives might act as prodrugs which
20 enhance the penetration of their carboxylic acid counterparts. However, this requires further
21 investigations by testing the major form of the compounds existing in the bacterial cells after
22 penetration of the compounds.

23 Compound **4c** exhibited MIC values ranging from 5 to 20 μ M against five different *S. aureus*
24 strains and MIC values ranging from 2.5 to 10 μ M against three different *S. epidermidis* strains.

Compound **4c** also showed an antibacterial activity against *E. faecalis* with MIC value of 2.5 μ M and MBC value of 5 μ M. The potency of compound **4c** against *E. faecalis* is significantly high when compared to the reference drug gentamicin, MIC value of gentamicin= 26.2 μ M, showing that this compound is a potent bactericidal.

Most importantly, compounds **4a** and **4c** revealed antibacterial activity, not only against different Gram-positive pathogens, but also against the Gram-negative bacterium *Y. pestis* KUMA with MIC values of 10 μ M and 5 μ M, respectively. On the other hand, none of the 2-(benzylidenehydrazono)-3-arylthiazolidin-4-one derivatives, described in Scheme 2, showed antibacterial activity.

Inhibition of biofilm formation

Many microbes form biofilm in response to many factors in which cells stick to each other on a surface. These adherent cells are frequently embedded within a self-produced matrix of extracellular polymeric substance. The factors, by which biofilm is formed, may include cellular recognition of specific or non-specific attachment sites on a surface. In some cases, the factors include the exposure of planktonic cells to sub-inhibitory concentrations of antibiotics. Biofilms are a serious problem for public health because of the increased resistance of biofilm-associated microorganisms to antimicrobial agents and the potential for these microorganisms to cause infections in patients with indwelling medical devices (Hoffman et al., 2005; Karatan and Watnick, 2009).

Unlike the antibacterial activity, the 2-(benzylidenehydrazono)-3-arylthiazolidin-4-one derivatives **9b** and **10a** were able to inhibit the biofilm formation in *S. epidermidis*, where they showed 70% to 80% inhibition at a concentration of 40 μ M. This highlighted the fact that this structure feature was crucial for biofilm inhibition activity. However, this was limited by the type of the substitution at position 4 of the 1,3-thiazolidin-4-one ring; where only the 4-unsubstituted derivative **9b** and the 4-

ethoxycarbonyl derivative **10a** were active as biofilm formation inhibitors. Generally, the presence of the acetic acid side chain at position 5 of the thiazolidinone ring (compounds **5a-c** and **11a,b**) resulted in analogues, lacking both antibacterial and biofilm inhibition activity.

CONCLUSION

We report herein the synthesis of new 1,3-thiazolidin-4-one derivatives and their *in vitro* antibacterial activity. Based on the previous biological results, we can suggest that 1,3-thiazolidin-4-one derivatives with an ethylester moiety at position 5 (compounds **4a** and **4c**) are good lead compounds for further biological evaluation as antibacterial agents. Compounds **4a** and **4c** were not only active against different Gram-positive pathogens, but also against the Gram-negative bacterium *Y. pestis*. The antibacterial activity of compounds **4a** and **4c** can be due to the potential MurB inhibition activity of the thiazolidin-4-one nucleus. In addition, compounds **9b** and **10a** revealed biofilm inhibition activity against *S. epidermidis* biofilm formation. These obtained results are encouraging for further synthesis of new 1,3-thiazolidin-4-one derivatives with different substitutions at positions 3 and 5, as potential antibacterial agents.

EXPERIMENTAL

Chemical syntheses

Materials and methods

¹H-NMR and ¹³C-NMR spectra were recorded on an *Avance* 400 nuclear magnetic resonance spectrometer, Bruker Biospin GmbH Rheinstetten, Germany (¹H 400.123 MHz, ¹³C 100.613 MHz). As an internal standard, the signals of the deuterated solvents were used (DMSO-*d*₆: ¹H 2.5 ppm, ¹³C 39.43 ppm). The following abbreviations describing the multiplicity are used: (s) singlet, (d) doublet, (t) triplet, (q) quartet, (dd) doublet of doublet. IR spectra were obtained with a Biorad

PharmalyzIR FT-IR spectrometer (Biorad, Cambridge, MA, USA). Melting points were measured using an apparatus Sanyo Gallenkamp (Sanyo Gallenkamp, Loughborough, UK) and were not corrected. Elemental microanalyses were performed at the microanalytical center; Al-Azhar University, Cairo, Egypt. Thin layer chromatography (TLC) was carried out on TLC aluminum sheets, silica gel F₂₅₄, (Merck KGaA, Darmstadt, Germany), and visualized in ultraviolet (UV) chamber. All chemicals were purchased from Sigma-Aldrich Chemicals (Deisenhofen, Germany), Acros Organics (Geel, Belgium) and VWR International (Darmstadt, Germany), and were used without further purification.

General procedures for the synthesis of 4-(3-substitutedthioureido)benzenesulfonamides (2a-c)

The appropriate isothiocyanate (12 mmol) was added to a solution of sulfanilamide **1** (10 mmol) in absolute ethanol (20 mL) then few drops of triethylamine were added to the solution and refluxed for 24 h. A white precipitate was formed, filtered off, dried and recrystallized from ethanol to give compounds **2a-c**.

4-(3-Methylthioureido)benzenesulfonamide (2a)

Yield, 88%; m.p. 222-224 °C; IR, cm⁻¹: 3313, 3294, 3132 (NH, NH₂), 3055 (CH arom.), 2943, 2870 (CH aliph.), 1249 (C=S), 1369, 1161 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ: 2.94 (d, 3H, CH₃), 7.25 (s, 2H, SO₂NH₂, exchangeable with D₂O), 7.62 (d, 2H, *J* = 8.51 Hz, CH_{arom.}), 7.74 (d, 2H, *J* = 8.95 Hz, CH_{arom.}), 7.97 (s, 1H, NH, exchangeable with D₂O), 9.84 (s, 1H, NH, exchangeable with D₂O). ¹³C-NMR (DMSO-*d*₆, ppm) δ: 31.07 (CH₃), 121.46, 126.21, 138.36, 142.59 (CH_{arom.}), 180.98 (C=S).

4-(3-Ethylthioureido)benzenesulfonamide (2b)

Yield, 92%; m.p. 209-211 °C; IR, cm⁻¹: 3352, 3298, 3155 (NH, NH₂), 3062 (CH arom.), 2974, 2890 (CH aliph.), 1249 (C=S), 1377, 1165 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ: 1.19 (t, 3H, *J* = 7.91 Hz, CH₃), 3.45 (q, 2H, *J* = 7.09 Hz, CH₂), 7.23 (s, 2H, SO₂NH₂), 7.61 (d, 2H, *J* = 8.62 Hz, CH_{arom.}), 7.73

(d, 2H, J = 8.9 Hz, CH_{arom.}), 7.95 (s, 1H, NH), 9.82 (s, 1H, NH). ¹³C-NMR (DMSO-*d*₆, ppm) δ : 13.92 (CH₃), 25.46 (CH₂), 121.50, 126.21, 138.38, 142.69 (CH_{arom.}), 179.99 (C=S).

4-(3-Phenylthioureido)benzenesulfonamide (2c)

Yield, 86%; m.p. 204-206 °C; IR, cm⁻¹: 3344, 3240, 3165 (NH, NH₂), 3008 (CH arom.), 1242 (C=S), 1334, 1157 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ : 7.15 (dd, 1H, CH_{arom.}), 7.28 (s, 2H, SO₂NH₂), 7.35 (dd, 2H, CH_{arom.}), 7.49 (d, 2H, CH_{arom.}), 7.70 (d, 2H, J = 8.73 Hz, CH_{arom.}), 7.75 (d, 2H, J = 8.61 Hz, CH_{arom.}), 10.02 (s, 1H, NH), 10.05 (s, 1H, NH). ¹³C-NMR (DMSO-*d*₆, ppm) δ : 122.30, 122.49, 123.60, 124.63, 126.03, 128.43, 139.07, 142.57 (CH_{arom.}), 179.48 (C=S).

General procedures for the synthesis of 4-(4-oxo-3-substituted-thiazolidin-2-ylideneamino)benzenesulfonamides (3a-c)

10 mmol of monochloroacetic acid and a catalytic amount of anhydrous sodium acetate were added to a solution of compound **2a**, **2b** or **2c** (10 mmol) in glacial acetic acid (20 mL). The mixture was refluxed for 24 h and left to cool then poured into crushed ice. The formed precipitate was filtered off and crystallized from ethanol to give the corresponding 1,3-thiazolidin-4-one derivatives **3a-c**.

4-(3-Methyl-4-oxo-thiazolidin-2-ylideneamino)benzenesulfonamide (3a)

Yield, 58%; m.p. 183-185 °C; IR, cm⁻¹: 3332, 3221 (NH₂), 3097 (CH arom.), 2943, 2851 (CH aliph.), 1712 (C=O), 1620 (C=N), 1377, 1153 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ : 3.17 (s, 3H, N-CH₃), 4.06 (s, 2H, CH₂), 7.09 (d, 2H, J = 8.51 Hz, CH_{arom.}), 7.31 (s, 2H, SO₂NH₂, exchangeable with D₂O), 7.80 (d, 2H, J = 8.82 Hz, CH_{arom.}). ¹³C-NMR (DMSO-*d*₆, ppm) δ : 29.07 (CH₂), 32.74 (CH₃), 121.16, 127.06, 139.62, 151.12 (CH_{arom.}), 156.89 (N=C), 171.80 (C=O). Anal. Calcd. For C₁₀H₁₁N₃O₃S₂ (285.34): C, 42.09; H, 3.89; N, 14.73. Found: C, 42.21; H, 3.93; N, 14.90.

4-(3-Ethyl-4-oxo-thiazolidin-2-ylideneamino)benzenesulfonamide (3b)

Yield, 64%; m.p. 169-171 °C; IR, cm⁻¹: 3329, 3255 (NH₂), 3080 (CH arom.), 2983, 2860 (CH aliph.), 1732 (C=O), 1643 (C=N), 1373, 1168 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ : 1.21 (t, 3H, J =

1 7.11 Hz, CH₃), 3.81 (q, 2H, *J* = 7.17 Hz, CH₃), 4.04 (s, 2H, CH₂), 7.09 (d, 2H, *J* = 8.49 Hz, CH_{arom.}),
2 7.31 (s, 2H, SO₂NH₂), 7.81 (d, 2H, *J* = 8.91 Hz, CH_{arom.}). ¹³C-NMR (DMSO-*d*₆, ppm) δ: 12.21
3 (CH₂CH₃), 32.73 (CH₂-C=O), 37.42 (CH₂CH₃), 121.25, 127.13, 139.71, 151.19 (CH_{arom.}), 156.11
4 (N=C), 171.64 (C=O). Anal. Calcd. For C₁₁H₁₃N₃O₃S₂ (299.37): C, 44.13; H, 4.38; N, 14.04.
5 Found: C, 44.22; H, 4.39; N, 14.15.

6 *4-(4-Oxo-3-phenylthiazolidin-2-ylideneamino)benzenesulfonamide (3c)*

7 Yield, 60%; m.p. 190-192 °C; IR, cm⁻¹: 3363, 3204 (NH₂), 3051 (CH arom.), 1724 (C=O), 1635
8 (C=N), 1373, 1153 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ: 4.16 (s, 2H, CH₂), 6.88 (d, 2H, CH_{arom.}),
9 7.09 (dd, 1H, CH_{arom.}), 7.34 (dd, 2H, CH_{arom.}), 7.42 (d, 2H, *J* = 8.88 Hz, CH_{arom.}), 7.45 (s, 2H,
10 SO₂NH₂), 7.53 (d, 2H, *J* = 8.97 Hz, CH_{arom.}). ¹³C-NMR (DMSO-*d*₆, ppm) δ: 32.74 (CH₂), 122.55,
11 124.09, 128.36, 128.89, 129.13, 135.19, 148.06, 155.78 (CH_{arom.}), 171.54 (N=C), 172.57 (C=O).
12 Anal. Calcd. For C₁₅H₁₃N₃O₃S₂ (347.41): C, 51.86; H, 3.77; N, 12.10. Found: C, 51.98; H, 3.75; N,
13 12.27.

14 *General procedures for the synthesis of ethyl 4-oxo-3-substituted-2-(4-*
15 *sulfamoylphenylimino)thiazolidine-5-carboxylates (4a-c)*

16 10 mmol of diethylbromomalonate and a catalytic amount of anhydrous sodium acetate were added
17 to a solution of compound **2a**, **2b** or **2c** (10 mmol) in glacial acetic acid (20 mL). The mixture was
18 refluxed for 24 h and left to cool then poured into crushed ice. The formed precipitate was filtered
19 off and crystallized from ethanol to give the corresponding 1,3-thiazolidin-4-one derivatives **4a-c**.

20 *Ethyl 3-methyl-4-oxo-2-(4-sulfamoylphenylimino)thiazolidine-5-carboxylate (4a)*

21 Yield, 46%; m.p. 106-108 °C; IR, cm⁻¹: 3356, 3255 (NH₂), 3070 (CH arom.), 2978, 2870 (CH
22 aliph.), 1724, 1698 (2C=O), 1369, 1157 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ: 1.25 (t, 3H, *J* = 7.21
23 Hz, CH₃), 3.19 (s, 3H, CH₃), 3.72 (q, 2H, *J* = 7.03 Hz, CH₂), 4.10 (s, 1H, CH), 7.09 (d, 2H, *J* = 8.63
24 Hz, CH_{arom.}), 7.32 (s, 2H, SO₂NH₂), 7.82 (d, 2H, *J* = 8.72 Hz, CH_{arom.}). ¹³C-NMR (DMSO-*d*₆, ppm)

1 δ : 13.52 (COOCH₂CH₃), 21.90 (N-CH₃), 29.15 (HC-C=O), 32.81 (COOCH₂CH₃), 121.24, 127.14,
2 139.70, 151.20 (CH_{arom.}), 155.51 (N=C), 171.05 (COOCH₂CH₃), 171.89 (N-C=O). Anal. Calcd. For
3 C₁₃H₁₅N₃O₅S₂ (357.41): C, 43.69; H, 4.23; N, 11.76. Found: C, 43.77; H, 4.25; N, 11.85.

4 *Ethyl 3-ethyl-4-oxo-2-(4-sulfamoylphenylimino)thiazolidine-5-carboxylate (4b)*

5 Yield, 40%; m.p. 159-161 °C; IR, cm⁻¹: 3544, 3461 (NH₂), 3070 (CH arom.), 2989, 2877 (CH
6 aliph.), 1751, 1721 (2C=O), 1390, 1198 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ : 1.13 (t, 3H, *J*= 7.18
7 Hz, CH₃), 1.19 (t, 3H, *J*= 7.34 Hz, CH₃), 3.74 (q, 2H, *J*= 7.51 Hz, CH₂), 3.84 (q, 2H, *J*= 7.42 Hz,
8 CH₂), 4.05 (s, 1H, CH), 7.09 (d, 2H, *J*= 8.59 Hz, CH_{arom.}), 7.79 (s, 2H, SO₂NH₂), 7.84 (d, 2H, *J*=
9 8.79 Hz, CH_{arom.}). ¹³C-NMR (DMSO-*d*₆, ppm) δ : 11.24 (CH₃CH₂), 13.41 (COOCH₂CH₃), 34.96
10 (CH₃CH₂), 56.42 (HC-C=O), 64.21 (COOCH₂CH₃), 121.22, 127.44, 133.57, 140.57 (CH_{arom.}),
11 155.29 (N=C), 164.78 (COOCH₂CH₃), 168.96 (N-C=O). Anal. Calcd. For C₁₄H₁₇N₃O₅S₂ (371.43):
12 C, 45.27; H, 4.61; N, 11.31. Found: C, 45.39; H, 4.69; N, 11.46.

13 *Ethyl 4-oxo-3-phenyl-2-(4-sulfamoylphenylimino)thiazolidine-5-carboxylate (4c)*

14 Yield, 53%; m.p. 126-128 °C; IR, cm⁻¹: 3356, 3259 (NH₂), 3062 (CH arom.), 2981, 2871 (CH
15 aliph.), 1728, 1701 (2C=O), 1369, 1153 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ : 1.23 (t, 3H, *J*= 7.65
16 Hz, CH₃), 4.21 (q, 2H, *J*= 7.71 Hz, CH₂), 4.32 (s, 1H, CH), 6.87 (dd, 1H, CH_{arom.}), 7.04 (dd, 2H,
17 CH_{arom.}), 7.29 (d, 2H, CH_{arom.}), 7.41 (d, 2H, *J*= 8.80 Hz, CH_{arom.}), 7.52 (s, 2H, SO₂NH₂), 7.76 (d,
18 2H, *J*= 8.91 Hz, CH_{arom.}). ¹³C-NMR (DMSO-*d*₆, ppm) δ : 13.86 (COOCH₂CH₃), 28.62 (HC-C=O),
19 32.75 (COOCH₂CH₃), 120.55, 120.94, 124.10, 127.02, 128.37, 128.90, 129.15, 129.54 (CH_{arom.}),
20 154.95 (N=C), 170.91 (COOCH₂CH₃), 171.50 (N-C=O). Anal. Calcd. For C₁₈H₁₇N₃O₅S₂ (419.47):
21 C, 51.54; H, 4.08; N, 10.02. Found: C, 51.63; H, 4.11; N, 10.09.

1 *General procedures for the synthesis of 2-(4-oxo-3-substituted-2-(4-*
2 *sulfamoylphenylimino)thiazolidin-5-yl)acetic acids (5a-c)*
3 10 mmol of maleic anhydride was added to a solution of compound **2a**, **2b** or **2c** (10 mmol) in
4 glacial acetic acid (20 mL), The mixture was refluxed for 24 h and left to cool then poured into
5 crushed ice. The formed precipitate was filtered off and crystallized from ethanol to give the
6 corresponding 1,3-thiazolidin-4-one derivatives **5a-c**.

7 *2-(3-Methyl-4-oxo-2-(4-sulfamoylphenylimino)thiazolidin-5-yl)acetic acid (5a)*

8 Yield, 61%; m.p. 160-162 °C; IR, cm^{-1} : 3356, 3205 (NH_2), 3100 (OH), 3052 (CH arom.), 2985,
9 2878 (CH aliph.), 1697, 1674 ($2\text{C}=\text{O}$), 1370, 1157 (SO_2). ^1H -NMR ($\text{DMSO}-d_6$, ppm) δ : 1.95 (d,
10 2H, $J= 6.52$ Hz, CH_2), 3.21 (s, 3H, CH_3), 4.54 (t, 1H, $J= 6.79$ Hz, CH), 7.05 (d, 2H, $J= 8.69$ Hz,
11 $\text{CH}_{\text{arom.}}$), 7.71 (s, 2H, SO_2NH_2), 7.80 (d, 2H, $J= 8.99$ Hz, $\text{CH}_{\text{arom.}}$), 10.56 (s, 1H, OH). ^{13}C -NMR
12 ($\text{DMSO}-d_6$, ppm) δ : 21.03 ($\text{N}-\underline{\text{C}}\text{H}_3$), 29.19 ($\underline{\text{C}}\text{H}_2$), 43.58 ($\text{HC}-\text{C}=\text{O}$), 118.39, 126.71, 138.53,
13 151.32 ($\underline{\text{C}}\text{H}_{\text{arom.}}$), 156.89 ($-\text{N}=\underline{\text{C}}$), 168.45 ($\underline{\text{C}}\text{OOH}$), 173.72 ($\underline{\text{C}}=\text{O}$). Anal. Calcd. For $\text{C}_{12}\text{H}_{13}\text{N}_3\text{O}_5\text{S}_2$
14 (343.38): C, 41.97; H, 3.82; N, 12.24. Found: C, 42.08; H, 3.80; N, 12.38.

15 *2-(3-Ethyl-4-oxo-2-(4-sulfamoylphenylimino)thiazolidin-5-yl)acetic acid (5b)*

16 Yield, 61%; m.p. 188-190 °C; IR, cm^{-1} : 3352, 3263 (NH_2), 3113 (OH), 3052 (CH arom.), 2997,
17 2865 (CH aliph.), 1701, 1658 ($2\text{C}=\text{O}$), 1334, 1157 (SO_2). ^1H -NMR ($\text{DMSO}-d_6$, ppm) δ : 1.21 (t, 3H,
18 $J= 7.33$ Hz, CH_3), 1.81 (d, 2H, $J= 7.01$ Hz, CH_2), 3.80 (q, 2H, $J= 7.64$ Hz, CH_2), 4.29 (t, 1H, $J=$
19 6.91 Hz, CH), 7.09 (d, 2H, $J= 8.90$ Hz, $\text{CH}_{\text{arom.}}$), 7.72 (s, 2H, SO_2NH_2), 7.78 (d, 2H, $J= 9.0$ Hz,
20 $\text{CH}_{\text{arom.}}$), 10.49 (s, 1H, OH). ^{13}C -NMR ($\text{DMSO}-d_6$, ppm) δ : 12.14 ($\underline{\text{C}}\text{H}_3\text{CH}_2$), 22.36 ($\underline{\text{C}}\text{H}_2$), 38.45
21 ($\text{CH}_3\underline{\text{C}}\text{H}_2$), 43.50 ($\text{HC}-\text{C}=\text{O}$), 121.30, 127.07, 139.63, 141.52 ($\underline{\text{C}}\text{H}_{\text{arom.}}$), 155.93 ($-\text{N}=\underline{\text{C}}$), 168.40
22 ($\underline{\text{C}}\text{OOH}$), 172.97 ($\underline{\text{C}}=\text{O}$). Anal. Calcd. For $\text{C}_{13}\text{H}_{15}\text{N}_3\text{O}_5\text{S}_2$ (357.41): C, 43.69; H, 4.23; N, 11.76.
23 Found: C, 43.77; H, 4.27; N, 11.83.

1 2-(4-Oxo-3-phenyl-2-(4-sulfamoylphenylimino)thiazolidin-5-yl)acetic acid (**5c**)
2 Yield, 63%; m.p. 171-173 °C; IR, cm⁻¹: 3348, 3300 (NH₂), 3215 (OH), 3066 (CH arom.), 2931,
3 2875 (CH aliph.), 1708, 1660 (2C=O), 1388, 1161 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ: 1.91 (d,
4 2H, *J*= 6.64 Hz, CH₂), 4.49 (t, 1H, *J*= 6.75 Hz, CH), 6.87 (dd, 1H, CH_{arom.}), 7.03 (dd, 2H, CH_{arom.}),
5 7.29 (d, 2H, CH_{arom.}), 7.46 (d, 2H, *J*= 8.92 Hz, CH_{arom.}), 7.74 (s, 2H, SO₂NH₂), 7.95 (d, 2H, *J*= 8.83
6 Hz, CH_{arom.}), 10.35 (s, 1H, OH). ¹³C-NMR (DMSO-*d*₆, ppm) δ: 21.02 (CH₂), 43.62 (HC-C=O),
7 120.71, 121.09, 122.93, 127.05, 128.47, 128.92, 129.18, 139.54 (CH_{arom.}), 155.82 (-N=C), 168.86
8 (COOH), 171.97 (C=O). Anal. Calcd. For C₁₇H₁₅N₃O₅S₂ (405.45): C, 50.36; H, 3.73; N, 10.36.
9 Found: C, 50.49; H, 3.71; N, 10.44.

10 *Synthesis of 4-isothiocyantobenzenesulfonamide (6)*

11 A solution of sulfanilamide **1** in water was prepared by stirring sulfanilamide **1** (10 mmol) in
12 distilled water (40 mL), containing hydrochloric acid (10 mmol), for 5 min. Thiophosgen (10
13 mmol) was added to the prepared solution and the mixture was stirred at room temperature for 2 h.
14 The formed precipitate was filtered off and dried to give compounds **6** (El-Gaby et al., 2009).

15 *Synthesis of N-(4-sulfamoylphenyl)hydrazinecarbothioamide (7)*

16 A mixture, of compound **6** (10 mmol) and excess amount of hydrazine hydrate in isopropanol (40
17 mL), was stirred at room temperature for 4 hours. The formed precipitate was filtered off and dried
18 to give compound **7** (Sriram et al., 2009).

19 *General procedures for the synthesis of 2-(4-(substituted)benzylidene)-N-(4-*

20 *sulfamoylphenyl)hydrazinecarbothioamides (8a,b)*

21 A mixture, of compound **7** (10 mmol) and the appropriate aldehyde (10 mmol) in methanol (30
22 mL), was refluxed for 5 h. The formed precipitate was filtered, while hot, and the obtained solid
23 was dried to give compounds **8a,b**.

1 *2-(4-Chorobenzylidene)-N-(4-sulfamoylphenyl)hydrazinecarbothioamide (8a)*

2 Yield, 59%; m.p. 240-242 °C; IR, cm⁻¹: 3288, 3245, 3131 (NH, NH₂), 3089 (CH arom.), 2978, 2873
3 (CH aliph.), 1587 (C=N), 1278 (C=S), 1393, 1158 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ: 6.70 (d,
4 2H, *J* = 8.48 Hz, CH_{arom.}), 7.25 (s, 2H, SO₂NH₂, exchangeable with D₂O), 7.56 (d, 2H, *J* = 8.84 Hz,
5 CH_{arom.}), 7.82 (d, 2H, *J* = 8.74 Hz, CH_{arom.}), 7.98 (d, 2H, *J* = 8.72 Hz, CH_{arom.}), 8.15 (s, 1H, -N=CH),
6 10.32 (s, 1H, NH, exchangeable with D₂O), 12.05 (s, 1H, NH, exchangeable with D₂O). ¹³C-NMR
7 (DMSO-*d*₆, ppm) δ: 125.42, 125.63, 129.07, 130.00, 132.82, 134.63, 140.35, 142.01 (CH_{arom.}),
8 142.15 (N=CH), 175.93 (C=S). Anal. Calcd. For C₁₄H₁₃ClN₄O₂S₂ (368.86): C, 45.59; H, 3.55; N,
9 15.19. Found: C, 45.65; H, 3.58; N, 15.32.

10 *2-(4-(Dimethylamino)benzylidene)-N-(4-sulfamoylphenyl)hydrazinecarbothioamide (8b)*

11 Yield, 55%; m.p. 225-227 °C; IR, cm⁻¹: 3333, 3245, 3135 (NH, NH₂), 3090 (CH arom.), 2974, 2899
12 (CH aliph.), 1587 (C=N), 1268 (C=S), 1364, 1154 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ: 2.98 (s, 6H,
13 N(CH₃)₂), 6.73 (d, 2H, *J* = 8.51 Hz, CH_{arom.}), 7.32 (s, 2H, SO₂NH₂), 7.70 (d, 2H, *J* = 8.56 Hz,
14 CH_{arom.}), 7.78 (d, 2H, *J* = 8.81 Hz, CH_{arom.}), 7.86 (d, 2H, *J* = 8.89 Hz, CH_{arom.}), 8.06 (s, 1H, -N=CH),
15 10.10 (s, 1H, NH), 11.76 (s, 1H, NH). ¹³C-NMR (DMSO-*d*₆, ppm) δ: 39.66 (N(CH₃)₂), 111.50,
16 120.82, 124.67, 125.50, 129.08, 139.77, 142.15, 151.55 (CH_{arom.}), 144.55 (N=CH), 174.47 (C=S).
17 Anal. Calcd. For C₁₆H₁₉N₅O₂S₂ (377.48): C, 50.91; H, 5.07; N, 18.55. Found: C, 50.99; H, 5.12; N,
18 18.71.

19 *General procedures for the synthesis of 4-(2-(4-(substituted)benzylidene)hydrazono)-4-*
20 *oxothiazolidin-3-yl)benzenesulfonamides (9a,b)*

21 10 mmol of monochloroacetic acid and a catalytic amount of anhydrous sodium acetate were added
22 to a solution of compound **8a** or **8b** (10 mmol) in glacial acetic acid (20 mL). The mixture was
23 refluxed for 24 h and left to cool then poured into crushed ice. The formed precipitate was filtered
24 off and crystallized from ethanol to give the corresponding 4-thiazolidinone derivatives **9a,b**.

1 4-(2-(4-Chlorobenzylidene)hydrazono)-4-oxothiazolidin-3-yl)benzenesulfonamide (**9a**)
2 Yield, 53%; m.p. 288-290 °C; IR, cm⁻¹: 3346, 3261 (NH₂), 3062 (CH arom.), 2969, 2885 (CH
3 aliph.), 1732 (C=O), 1620 (C=N), 1393, 1156 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ: 4.13 (s, 2H,
4 CH₂), 7.39 (d, 2H, *J*= 8.78 Hz, CH_{arom.}), 7.50 (s, 2H, SO₂NH₂, exchangeable with D₂O), 7.54 (d,
5 2H, *J*= 8.66 Hz, CH_{arom.}), 7.72 (d, 2H, *J*= 8.94 Hz, CH_{arom.}), 7.89 (d, 2H, *J*= 8.52 Hz, CH_{arom.}), 8.30
6 (s, 1H, N=CH). ¹³C-NMR (DMSO-*d*₆, ppm) δ: 32.50 (CH₂), 126.53, 128.84, 129.07, 130.00,
7 132.87, 135.39, 137.69, 144.13 (CH_{arom.}), 156.96 (N=CH), 165.49 (N-C=N), 171.79 (C=O). Anal.
8 Calcd. For C₁₆H₁₃ClN₄O₃S₂ (408.88): C, 47.00; H, 3.20; N, 13.70. Found: C, 47.08; H, 3.22; N,
9 13.83.

10 4-(2-(4-(Dimethylamino)benzylidene)hydrazono)-4-oxothiazolidin-3-yl)benzenesulfonamide (**9b**)
11 Yield, 46%; m.p. 218-220 °C; IR, cm⁻¹: 3317, 3263 (NH₂), 3050 (CH arom.), 2920, 2895 (CH
12 aliph.), 1697 (C=O), 1596 (C=N), 1370, 1162 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ: 2.97 (s, 6H,
13 N(CH₃)₂), 4.09 (s, 2H, CH₂), 7.21 (d, 2H, *J*= 8.63 Hz, CH_{arom.}), 7.50 (s, 2H, SO₂NH₂), 7.56 (d, 2H,
14 *J*= 8.71 Hz, CH_{arom.}), 7.79 (d, 2H, *J*= 8.99 Hz, CH_{arom.}), 7.94 (d, 2H, *J*= 9.21 Hz, CH_{arom.}), 8.15 (s,
15 1H, N=CH). ¹³C-NMR (DMSO-*d*₆, ppm) δ: 30.57 (CH₂), 39.92 (N(CH₃)₂), 110.96, 112.96, 121.17,
16 126.39, 128.89, 134.08, 136.75, 151.26 (CH_{arom.}), 144.09 (N=CH), 165.80 (N-C=N), 174.79 (C=O).
17 Anal. Calcd. For C₁₈H₁₉N₅O₃S₂ (417.51): C, 51.78; H, 4.59; N, 16.77. Found: C, 51.89; H, 4.62; N,
18 16.89.

19 *General procedures for the synthesis of ethyl 2-(4-(substituted)benzylidene)hydrazono)-4-oxo-3-(4-*
20 *sulfamoylphenyl)thiazolidine-5-carboxylates (10a,b)*

21 10 mmol of diethylbromomalonate and a catalytic amount of anhydrous sodium acetate were added
22 to a solution of compound **8a** or **8b** (10 mmol) in glacial acetic acid (20 mL). The mixture was
23 refluxed for 24 h and left to cool then poured into crushed ice. The formed precipitate was filtered
24 off and crystallized from ethanol to give the corresponding 1,3-thiazolidin-4-one derivatives **10a,b**.

1 *Ethyl 2-(4-chlorobenzylidene)hydrazono)-4-oxo-3-(4-sulfamoylphenyl)thiazolidine-5-carboxylate*
2 **(10a)**

3 Yield, 48%; m.p. 159-161 °C; IR, cm⁻¹: 3359, 3265 (NH₂), 3092 (CH arom.), 2980, 2890 (CH
4 aliph.), 1739, 1619 (2C=O), 1580 (C=N), 1380, 1162 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ: 1.23 (t,
5 3H, *J*= 7.22 Hz, CH₃), 4.21 (q, 2H, *J*= 7.16 Hz, CH₂), 4.33 (s, 1H, CH), 7.64 (d, 2H, *J*= 8.71 Hz,
6 CH_{arom.}), 7.66 (s, 2H, SO₂NH₂, exchangeable with D₂O), 7.81 (d, 2H, *J*= 8.69 Hz, CH_{arom.}), 7.97 (d,
7 2H, *J*= 8.98 Hz, CH_{arom.}), 8.07 (d, 2H, *J*= 8.95 Hz, CH_{arom.}), 8.50 (s, 1H, N=CH). ¹³C-NMR
8 (DMSO-*d*₆, ppm) δ: 13.56 (CH₃), 25.46 (HC-C=O), 62.01 (CH₂), 126.58, 128.89, 129.12, 130.12,
9 132.93, 135.45, 137.73, 144.18 (CH_{arom.}), 148.03 (N=CH), 155.21 (N-C=N), 164.21
10 (COOCH₂CH₃), 171.89 (C=O). Anal. Calcd. For C₁₉H₁₇ClN₄O₅S₂ (480.95): C, 47.45; H, 3.56; N,
11 11.65. Found: C, 47.59; H, 3.60; N, 11.79.

12 *Ethyl 2-(4-(dimethylamino)benzylidene)hydrazono)-4-oxo-3-(4-sulfamoylphenyl)-thiazolidine-5-*
13 *carboxylate (10b)*

14 Yield, 40%; m.p. 180-182 °C; IR, cm⁻¹: 3352, 3260 (NH₂), 3075 (CH arom.), 2980, 2891 (CH
15 aliph.), 1725, 1612 (2C=O), 1592 (C=N), 1368, 1196 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm) δ: 1.18 (t,
16 3H, *J*= 7.51 Hz, CH₃), 2.86 (s, 6H, N(CH₃)₂), 4.11 (q, 2H, *J*= 7.49 Hz, CH₂), 4.29 (s, 1H, CH), 7.07
17 (d, 2H, *J*= 8.80 Hz, CH_{arom.}), 7.31 (s, 2H, SO₂NH₂), 7.53 (d, 2H, *J*= 8.90 Hz, CH_{arom.}), 7.62 (d, 2H,
18 *J*= 9.10 Hz, CH_{arom.}), 7.93 (d, 2H, *J*= 8.68 Hz, CH_{arom.}), 8.18 (s, 1H, N=CH). ¹³C-NMR (DMSO-*d*₆,
19 ppm) δ: 13.93 (CH₃), 29.90 (N(CH₃)₂), 39.96 (HC-C=O), 60.71 (CH₂), 106.88, 107.70, 110.01,
20 125.87, 127.44, 129.49, 132.08, 148.14 (CH_{arom.}), 145.85 (N=CH), 188.66 (COOCH₂CH₃), 189.20
21 (C=O). Anal. Calcd. For C₂₁H₂₃N₅O₅S₂ (489.57): C, 51.52; H, 4.74; N, 14.31. Found: C, 51.63; H,
22 4.79; N, 14.42.

1 *General procedures for the synthesis of 2-(2-(4-(substituted)benzylidene)hydrazono)-4-oxo-3-(4-*
2 *sulfamoylphenyl)thiazolidin-5-yl)acetic acids (11a,b)*

3 10 mmol of maleic anhydride was added to a solution of compound **8a** or **8b** (10 mmol) in glacial
4 acetic acid (20 mL). The mixture was refluxed for 24 h and left to cool then poured into crushed
5 ice. The formed precipitate was filtered off and crystallized from ethanol to give the corresponding
6 1,3-thiazolidin-4-one derivatives **11a,b**.

7 *2-(-2-(4-Chlorobenzylidene)hydrazono)-4-oxo-3-(4-sulfamoylphenyl)thiazolidin-5-yl)acetic acid*
8 *(11a)*

9 Yield, 39%; m.p. 229-231 °C; IR, cm⁻¹: 3353, 3256 (NH₂), 3111 (OH), 3061 (CH arom.), 2933,
10 2860 (CH aliph.), 1705, 1699 (2C=O), 1617 (C=N), 1385, 1160 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm)
11 δ: 3.10 (d, 2H, *J*= 6.50 Hz, CH₂), 4.58 (t, 1H, *J*= 6.87 Hz, CH), 7.45 (d, 2H, *J*= 8.88 Hz, CH_{arom.}),
12 7.57 (s, 2H, SO₂NH₂, exchangeable with D₂O), 7.61 (d, 2H, *J*= 8.92 Hz, CH_{arom.}), 7.76 (d, 2H, *J*=
13 8.51 Hz, CH_{arom.}), 7.98 (d, 2H, *J*= 8.59 Hz, CH_{arom.}), 8.36 (s, 1H, N=CH), 10.86 (s, 1H, OH). ¹³C-
14 NMR (DMSO-*d*₆, ppm) δ: 21.03 (CH₂), 42.50 (CH), 126.43, 128.96, 129.32, 130.00, 132.89,
15 135.35, 137.82, 144.13 (CH_{arom.}), 156.83 (N=CH), 171.97 (N-C=N), 173.65 (C=O), 173.90 (C=O).
16 Anal. Calcd. For C₁₈H₁₅ClN₄O₅S₂ (466.92): C, 46.30; H, 3.24; N, 12.00. Found: C, 46.42; H, 3.26;
17 N, 12.14.

18 *2-(2-(4-(Dimethylamino)benzylidene)hydrazono)-4-oxo-3-(4-sulfamoylphenyl)thiazolidin-5-*
19 *yl)acetic acid (11b)*

20 Yield, 32%; m.p. 159-161 °C; IR, cm⁻¹: 3362, 3226 (NH₂), 3120 (OH), 3052 (CH arom.), 2914,
21 2865 (CH aliph.), 1709, 1695 (2C=O), 1593 (C=N), 1371, 1154 (SO₂). ¹H-NMR (DMSO-*d*₆, ppm)
22 δ: 2.96 (s, 6H, N(CH₃)₂), 3.11 (d, 2H, *J*= 6.59 Hz, CH₂), 4.55 (t, 1H, *J*= 6.88 Hz, CH), 6.72 (d, 2H,
23 *J*= 8.61 Hz, CH_{arom.}), 7.52 (s, 2H, SO₂NH₂), 7.56 (d, 2H, *J*= 8.99 Hz, CH_{arom.}), 7.74 (d, 2H, *J*= 9.01
24 Hz, CH_{arom.}), 7.96 (d, 2H, *J*= 8.70 Hz, CH_{arom.}), 8.15 (s, 1H, N=CH), 10.75 (s, 1H, OH). ¹³C-NMR

1 (DMSO-*d*₆, ppm) δ : 36.74 ($\underline{\text{CH}_2}$), 39.76 ($\text{N}(\underline{\text{CH}_3})_2$), 42.45 ($\underline{\text{CH}}$), 111.53, 121.08, 126.41, 128.80,
2 137.90, 143.91, 151.94 161.04 ($\underline{\text{CH}}_{\text{arom.}}$), 158.14 ($\text{N}=\underline{\text{CH}}$), 171.65 ($\text{N}-\underline{\text{C}}=\text{N}$), 173.34 ($\underline{\text{C}}=\text{O}$), 173.86
3 ($\underline{\text{C}}=\text{O}$). Anal. Calcd. For $\text{C}_{20}\text{H}_{21}\text{N}_5\text{O}_5\text{S}_2$ (475.54): C, 50.51; H, 4.45; N, 14.73. Found: C, 50.63; H,
4 4.49; N, 14.86.

5

6 **X-ray crystallography**

7 Suitable crystals for X-ray single crystal diffraction were selected, coated in perfluoropolyether oil,
8 and mounted on MiTeGen sample holders. Diffraction data of the sample were collected on a
9 Nonius Kappa three circle diffractometer utilizing mirror monochromated $\text{MoK}\alpha$ radiation ($\lambda =$
10 0.71073 \AA) from a rotating anode tube run at 50 V and 30 mA. The diffractometer is equipped with
11 a Bruker ApexII area detector and an open flow N_2 Cryoflex II (Bruker) device. Measurements
12 were performed at 100 K. For data reduction, the Bruker Apex2 software suite (Bruker AXS), was
13 used. Using **Olex2** (Dolomanov et al., 2009), the structure was solved with the **ShelXS-97**
14 (Sheldrick, 2008) structure solution program using direct methods solution method. The model was
15 refined with **XL** (Sheldrick, 2008) using Least Squares minimization. All non-hydrogen atom
16 positions were located from the Fourier maps and refined anisotropically. Hydrogen atom positions
17 were calculated using a riding model in geometric positions and refined isotropically.

18 Cambridge Structural Database (CSD) number: CCDC 1004668.

19 Crystal Data: $\text{C}_{10}\text{H}_{11}\text{N}_3\text{O}_3\text{S}_2$, $M_r = 285.34$, triclinic, P-1, $a = 9.8121(4) \text{ \AA}$, $b = 10.2076(5) \text{ \AA}$, $c =$
20 $24.6210(10) \text{ \AA}$, $\alpha = 83.992(2)^\circ$, $\beta = 82.035(2)^\circ$, $\gamma = 77.674(2)^\circ$, $V = 2378.71(18) \text{ \AA}^3$, $T = 100 \text{ K}$, $Z =$
21 8 , $Z' = 4$, $\mu (\text{MoK}\alpha) = 0.451$, 21120 reflections measured, 9859 unique ($R_{\text{int}} = 0.0337$) which were
22 used in all calculations. The final wR_2 was 0.2419 (all data) and R_1 was 0.0747 ($I \geq 2\sigma(I)$).

1 **Antibacterial activity**

2 Pure compounds were dissolved in sufficient volume of dimethylsulfoxide (DMSO) to make a final
3 concentration of 20 mM. Bacterial strains (*S. aureus* NCTC 8325, *S. aureus* HG001, *S. aureus*
4 MA12, *S. aureus* RN1, *S. aureus* Xen29, *S. epidermidis* RP62A, *S. epidermidis* 195, *S. epidermidis*
5 047, *E. faecalis* JH212, *E. faecium* 6413, *E.coli* 536, *P. aeruginosa*, *Y. pestis* KUMA, and *Y.*
6 *pseudotuberculosis* 252 01A) were cultivated overnight at 37 °C (30 °C for *Yersinia*) in Luria-
7 Bertani medium (per liter: 5 g NaCl, 5 g yeast extract, 10 g tryptone) in a shaking incubator.

8 On the next day, the overnight culture was diluted 1:100 in Müller-Hinton broth (23 g per Liter)
9 and again incubated until the cells reached the exponential growth phase. Approximately, 1×10^5
10 cells/mL were incubated with various concentrations of the compounds (40, 20, 10, 5, 2.5, 1.25,
11 0.625, and 0.3125 μ M) at 37°C for 18 h (30°C for 48 h for *Yersinia*) to make a final volume of 200
12 μ L in a 96-well plate. The final concentration of DMSO was 0.8% in each well.

13 After incubation, the optical density of the cultures was determined at 550 nm wavelength using an
14 ELISA microplate reader (MutlisKan Ascent, Thermo Fisher Scientific) with respect to the control
15 without bacteria. The lowest concentration of a tested compound, where no bacterial growth is
16 detectable, was determined as minimum inhibitory concentration (MIC). From substances whose
17 MIC is less than 20 μ M, the overnight cultures from the wells where no bacterial growth was
18 detected were plated on LB agar plates and incubated again overnight. The compound
19 concentration, at which no growth of the bacteria was detectable, was determined as the minimum
20 bactericidal concentration (MBC).

21 **Inhibition of biofilm formation**

22 Quantitative biofilm of *S. epidermidis* RP62A (ATCC 32984) measurement was done in a
23 microtiter assay. Bacteria were grown overnight in Trypticase Soy Broth / 0.25% glucose (Becton
24 Dickinson). 100 μ L of a 1:200 dilution of the overnight culture, with fresh medium, was transferred

to 96-well tissue culture plates (Greiner, Nürtingen, Germany) added to 100 μ L of a serial dilution of the test compounds in medium. Each compound concentration was measured in five replicates. The DMSO concentration in all wells was 0.8%. Following overnight incubation at 37°C, the optical density at 550 nm (OD₆₀₀) of the bacteria was measured and the cultures were poured out. The plates were washed three times with phosphate-buffered saline and the remaining bacteria were fixed by air drying at 60 °C. After staining with 0.4% crystal violet solution, the optical density of the adherent biofilm was determined at 490 nm. Values >0.120 at compound concentrations, with no effect on the bacterial growth in culture, were regarded as biofilm positive.

1 **ACKNOWLEDGEMENTS**

2 We thank Elena Katzowitsch and Tobias Ölschläger (Institute for Molecular Infection Biology,
3 University of Würzburg) for the antibacterial screening, which was funded by the Deutsche
4 Forschungsgemeinschaft (SFB 630, Z1). We also thank the Institute of Inorganic Chemistry,
5 University of Würzburg, for performing the X-ray measurement.

6

7 The authors declare that they have no conflicts of interest.

8

9

10

11

12

13

14

15

16

17

18

19

20


21

REFERENCES

- Allen, F.H., Kennard, O., Watson, D.G., Brammer, L., Orpen, A.G., and Taylor, R. (1987). Tables of bond lengths determined by X-ray and neutron diffraction. Part 1. Bond lengths in organic compounds. *Journal of the Chemical Society, Perkin Transactions 2*, S1-S19.
- Andres, C.J., Bronson, J.J., D'Andrea, S.V., Deshpande, M.S., Falk, P.J., Grant-Young, K.A., Harte, W.E., Ho, H.T., Misco, P.F., Robertson, J.G., *et al.* (2000). 4-Thiazolidinones: novel inhibitors of the bacterial enzyme MurB. *Bioorg Med Chem Lett* 10, 715-717.
- Aridoss, G., Amirthaganesan, S., Kim, M.S., Kim, J.T., and Jeong, Y.T. (2009). Synthesis, spectral and biological evaluation of some new thiazolidinones and thiazoles based on t-3-alkyl-r-2,c-6-diaryl piperidin-4-ones. *Eur J Med Chem* 44, 4199-4210.
- Bassetti, M., Merelli, M., Temperoni, C., and Astilean, A. (2013). New antibiotics for bad bugs: where are we? *Ann Clin Microbiol Antimicrob* 12, 22.
- Butler, M.S., Blaskovich, M.A., and Cooper, M.A. (2013). Antibiotics in the clinical pipeline in 2013. *J Antibiot (Tokyo)* 66, 571-591.
- Courvalin, P. (2006). Vancomycin resistance in gram-positive cocci. *Clin Infect Dis* 42 *Suppl 1*, S25-34.
- Dahl, A., and Bruun, N.E. (2013). Enterococcus faecalis infective endocarditis: focus on clinical aspects. *Expert Rev Cardiovasc Ther* 11, 1247-1257.
- de Perio, M.A., Yarnold, P.R., Warren, J., and Noskin, G.A. (2006). Risk factors and outcomes associated with non-Enterococcus faecalis, non-Enterococcus faecium enterococcal bacteremia. *Infect Control Hosp Epidemiol* 27, 28-33.
- Deshpande, L.M., Fritsche, T.R., Moet, G.J., Biedenbach, D.J., and Jones, R.N. (2007). Antimicrobial resistance and molecular epidemiology of vancomycin-resistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. *Diagn Microbiol Infect Dis* 58, 163-170.
- Dolomanov, O.V., Bourhis, L.J., Gildea, R.J., Howard, J.A.K., and Puschmann, H. (2009). OLEX2: a complete structure solution, refinement and analysis program. *Journal of Applied Crystallography* 42, 339-341.
- El-Gaby, M.S., El-Hag Ali, G.A., El-Maghraby, A.A., Abd El-Rahman, M.T., and Helal, M.H. (2009). Synthesis, characterization and in vitro antimicrobial activity of novel 2-thioxo-4-thiazolidinones and 4,4'-bis(2-thioxo-4-thiazolidinone-3-yl)diphenylsulfones. *Eur J Med Chem* 44, 4148-4152.
- French, G.L. (2006). Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin. *The Journal of antimicrobial chemotherapy* 58, 1107-1117.
- Gomes, F., Teixeira, P., and Oliveira, R. (2014). Mini-review: Staphylococcus epidermidis as the most frequent cause of nosocomial infections: old and new fighting strategies. *Biofouling* 30, 131-141.
- Gopalakrishnan, M., Thanusu, J., and Kanagarajan, V. (2009). Design, synthesis, spectral analysis and in vitro microbiological evaluation of 2-phenyl-3-(4,6-diarylpyrimidin-2-yl)thiazolidin-4-ones. *J Enzyme Inhib Med Chem* 24, 1088-1094.
- Hoffman, L.R., D'Argenio, D.A., MacCoss, M.J., Zhang, Z., Jones, R.A., and Miller, S.I. (2005). Aminoglycoside antibiotics induce bacterial biofilm formation. *Nature* 436, 1171-1175.
- Jain, A.K., Vaidya, A., Ravichandran, V., Kashaw, S.K., and Agrawal, R.K. (2012). Recent developments and biological activities of thiazolidinone derivatives: a review. *Bioorg Med Chem* 20, 3378-3395.

- Karatan, E., and Watnick, P. (2009). Signals, regulatory networks, and materials that build and break bacterial biofilms. *Microbiol Mol Biol Rev* 73, 310-347.
- Kumarasamy, K.K., Toleman, M.A., Walsh, T.R., Bagaria, J., Butt, F., Balakrishnan, R., Chaudhary, U., Doumith, M., Giske, C.G., Irfan, S., *et al.* (2010). Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. *Lancet Infect Dis* 10, 597-602.
- Lewis, K. (2013). Platforms for antibiotic discovery. *Nat Rev Drug Discov* 12, 371-387.
- Namvar, A.E., Bastarahang, S., Abbasi, N., Ghehi, G.S., Farhadbakhtiarian, S., Arezi, P., Hosseini, M., Baravati, S.Z., Jokar, Z., and Chermahin, S.G. (2014). Clinical characteristics of *Staphylococcus epidermidis*: a systematic review. *GMS Hyg Infect Control* 9, Doc23.
- Otto, M. (2009). *Staphylococcus epidermidis*--the 'accidental' pathogen. *Nat Rev Microbiol* 7, 555-567.
- Pechous, R.D., Sivaraman, V., Stasulli, N.M., and Goldman, W.E. (2015). Pneumonic Plague: The Darker Side of *Yersinia pestis*. *Trends Microbiol.*
- Pendleton, J.N., Gorman, S.P., and Gilmore, B.F. (2013). Clinical relevance of the ESKAPE pathogens. *Expert Rev Anti Infect Ther* 11, 297-308.
- Poyraz, O., Jeankumar, V.U., Saxena, S., Schnell, R., Haraldsson, M., Yogeeswari, P., Sriram, D., and Schneider, G. (2013). Structure-guided design of novel thiazolidine inhibitors of O-acetyl serine sulfhydrylase from *Mycobacterium tuberculosis*. *J Med Chem* 56, 6457-6466.
- Romling, U., and Balsalobre, C. (2012). Biofilm infections, their resilience to therapy and innovative treatment strategies. *J Intern Med* 272, 541-561.
- Roth, J.S., and Degering, E.F. (1945). The Preparation of Sulfanilamide Derivatives Containing a Urea or Thiourea Grouping. *Journal of the American Chemical Society* 67, 126-128.
- Sayyed, M., Mokle, S., Bokhare, M., Mankar, A., Surwase, S., Bhusare, S., and Vibhute, Y. (2006). Synthesis of some new 2, 3-diaryl-1, 3-thiazolidin-4-ones as antibacterial agents. *ARKIVOC*, 187-192.
- Sheldrick, G.M. (2008). A short history of SHELX. *Acta Crystallogr A* 64, 112-122.
- Sriram, D., Yogeeswari, P., Dhakla, P., Senthilkumar, P., Banerjee, D., and Manjashetty, T.H. (2009). 5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species. *Bioorg Med Chem Lett* 19, 1152-1154.
- Tong, S.Y., Davis, J.S., Eichenberger, E., Holland, T.L., and Fowler, V.G., Jr. (2015). *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microbiol Rev* 28, 603-661.
- Valour, F., Chebib, N., Gillet, Y., Reix, P., Laurent, F., Chidiac, C., and Ferry, T. (2013). [*Staphylococcus aureus* broncho-pulmonary infections]. *Rev Pneumol Clin* 69, 368-382.
- Verma, A., and Saraf, S.K. (2008). 4-thiazolidinone--a biologically active scaffold. *Eur J Med Chem* 43, 897-905.
- Vicini, P., Geronikaki, A., Anastasia, K., Incerti, M., and Zani, F. (2006). Synthesis and antimicrobial activity of novel 2-thiazolylimino-5-arylidene-4-thiazolidinones. *Bioorg Med Chem* 14, 3859-3864.
- Vicini, P., Geronikaki, A., Incerti, M., Zani, F., Dearden, J., and Hewitt, M. (2008). 2-Heteroarylimino-5-benzylidene-4-thiazolidinones analogues of 2-thiazolylimino-5-benzylidene-4-thiazolidinones with antimicrobial activity: synthesis and structure-activity relationship. *Bioorg Med Chem* 16, 3714-3724.

1 **Scheme 1:** Synthesis of compounds **3a-c**, **4a-c** and **5a-c**.



4

5

6

7 Reagents and conditions: (i) $R\text{-NCS}$ / EtOH / TEA / reflux 24 h. (ii) ClCH_2COOH / AcOH /

8 anhydrous CH_3COONa / reflux 24 hr. (iii) Diethylbromomalonate / AcOH / anhydrous CH_3COONa

9 / reflux 24 h. (iv) Maleic anhydride / AcOH / reflux 24 h.

2

2



4

5 Reagents and conditions: (i) CSCl_2 / H_2O / HCl / stirring RT / 2 h. (ii) $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ / isopropanol /

6 stirring RT / 2 h. (iii) Ar-CHO / MeOH / reflux 5 h. (iv) ClCH₂COOH / AcOH / anhydrous

7 CH_3COONa / reflux 24 hr. (v) Diethylbromomalonate / AcOH / anhydrous CH_3COONa / reflux 24


8 h. (vi) Maleic anhydride / AcOH / reflux 24 h.

9


10

11

12



(a) Single molecule and naming scheme.



(b) Asymmetric unit with indication of hydrogen

Figure 1: Molecular structure of compound **3a** as determined by X-ray single crystal diffraction:

a) molecule and naming scheme and b) asymmetric unit with hydrogen bonds. Element (colour): Carbon (grey), oxygen (red), nitrogen (blue), sulfur (yellow), hydrogen (light grey). Atomic displacement parameters are drawn at 50% probability.




Table 1: Antibacterial activity of the tested compounds **4a** and **4c**

| Tested bacterial strain | | Compound 4a | | Compound 4c | | Gentamycin | Tetracycline |
|-------------------------|--------------------------------------|---------------------------|----------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| | | MIC* (μM) | MBC** (μM) | MIC (μM) | MBC (μM) | MIC (μM) | MIC (μM) |
| Gram-positive | <i>S. aureus</i> 8325 | 10 | >40 | 5 | >40 | 0.21 | NT*** |
| | <i>S. aureus</i> HG001 | 10 | >40 | 5 | >40 | NT | NT |
| | <i>S. aureus</i> MA12 | 10 | >40 | 5 | >40 | NT | NT |
| | <i>S. aureus</i> RN1 | 40 | >40 | 20 | >40 | NT | NT |
| | <i>S. aureus</i> Xen29 | 10 | >40 | 5 | >40 | NT | NT |
| | <i>S. epidermidis</i> RP62A | 5 | >40 | 5 | >40 | NT | 0.83 |
| | <i>S. epidermidis</i> 195 | 10 | >40 | 10 | >40 | NT | NT |
| | <i>S. epidermidis</i> 047 | 5 | >40 | 2.5 | >40 | NT | NT |
| | <i>E. faecalis</i> JH212 | 5 | 10 | 2.5 | 5 | 26.2 | NT |
| | <i>E. faecium</i> 6413 | >40 | >40 | >40 | >40 | NT | 0.83 |
| Gram-negative | <i>E. coli</i> 536 | >40 | >40 | >40 | >40 | 0.83 | NT |
| | <i>P. aeruginosa</i> | >40 | >40 | >40 | >40 | 3.4 | NT |
| | <i>Y. pestis</i> KUMA | 10 | >40 | 5 | >40 | 1.7 | NT |
| | <i>Y. pseudotuberculosis</i> 252 01A | >40 | >40 | >40 | >40 | 1.7 | NT |

* MIC: Minimal Inhibitory Concentration

** MBC: Minimal Bactericidal Concentration

*** NT: Not tested